Subscribe to the gold package and get unlimited access to Shamra Academy
Register a new userSubcutaneous Betamethasone Phosphate Sodium Injection as a Treatment for Chalazion
حقن البيتاميتازون فوسفات الصوديوم تحت الجلد كعلاج للبردة
1668
0 30
0
(
0
)
Added by
Tishreen University ورقة بحثية
Publication date
2013
fields
Medicine
and research's language is
العربية
Authors
قحطان جلول( باحث )
Created by
Shamra Editor
Ask ChatGPT about the research
دراسة فعالية حقن البيتاميتازون فوسفات الصوديوم تحت الجلد لمعالجة البردة. أجري البحث في مشفى الأسد الجامعي, جامعة تشرين, اللاذقية, في الفترة بين كانون الثاني من عام 2009 وكانون الأول عام 2010. تضمنت الدراسة 30 مريضاً تتراوح أعمارهم بين سنة واحدة و 54 سنة لديهم بردة وتمت معالجتهم بحقن (0.2 مل) من البيتاميتازون فوسفات الصوديوم في النسيج تحت الجلد حول البردة من قبل نفس الطبيب ودون استخدام أي مخدر موضعي, ثم تمت مراقبة المريض بعد أسبوعين من الحقن وتمت إعادة الحقن لمرة واحدة عند عدم ملاحظة تراجع في حجم البردة بعد أسبوعين من الحقن بجرعة تساوي نصف الجرعة الأولى (0.1 مل) علماً أنه تم الحقن مرتين كحد أقصى بفارق أسبوعين بينهما. تم متابعة 30 مريضاً لديه بردة وتمت معالجتهم بحقن البيتاميتازون فوسفات الصوديوم في النسيج تحت الجلد حول البردة فكانت النتائج الآتية: في 27 مريض (90% ) اختفت البردة عندهم بشكل تام . في 16 مريض (53.3%) اختفت البردة عندهم بعد أول حقن, و11 مريضاً (36.7%) اختفت البردة عندهم بعد الحقنة الثانية. وبقي 3 مرضى (10%) لم يستجيبوا للمعالجة. -حجم البردة حتى وقت الحضور إلى العيادة لم تؤثر بشكل كبير على نتيجة المعالجة . تطور لدى مريضين فقد صباغ موضعي في منطقة الحقن, و لم تظهر أية اختلاطات أخرى . إن استعمال حقن البيتاميتازون فوسفات الصوديوم تحت الجلد علاج بسيط وفعال للبردة ومن ناحية أخرى فإن المقارنة مع الحالة السريرية تحدد الاستطباب .
The study aims to investigate the efficacy of subcutaneous Betamethasone phosphate sodium injection in the treatment of chalazion. The research was carried out in Al-Assad Hospital, Tishreen University, Lattakia, in the period from January 2009 to December 2010. The study included 30 patients; their age ranged between 1-54 years. The patients had chalazion treated with an injection (0.2ml) of Betamethasone phosphate sodium in the subcutaneous tissue around the lesion. All injections were given by a single ophthalmologist. No local or topical anaesthetic was used. The patients were monitored after 2 weeks. The injection (half of the first dose 0.1ml) was repeated when the chalazion did not reduce, with a maximum of two more injections given over a 2-week interval. Thirty patients with chalazion were followed up and treated with injection of Betamethasone phosphate sodium into the subcutaneous tissue around the lesion. In 27 patients (90%), the lesion subsided completely. 16 patients (53.3%) had lesions that subsided with one injection. 11 patients (36.7%) had lesions that subsided after the second injection. 3 patients (10%) did not respond to the treatment. The size and duration of the chalazion up till the time of the patients’ visit to the clinic did not significantly affect the outcome of the treatment. Two patients developed depigmentation of the skin at the site of injection. No other major complications were encountered. Subcutaneous injection of the Betamethasone phosphate sodium appears to be a simple and effective treatment for chalazion. Further comparative clinical cases are indicated
References used
CHUNG, F; LAI, S; LI, S. Subcutaneous extralesional triamcinolone acetonide injection versus conservative management in the treatment of chalazion. Hong Kong Med J, Vol. 12, N. 4, 2006, 278-281
PERRY, D; SERNIUK, A. Conservative treatment of chalazia. Ophthalmology, Vol. 87, N. 3, 1980, 218-221
PIZZARELLO, D; JAKOBIEC, A;HOFELDT, J; PODOLSKY, M; SILVERS,N. Intralesional corticosteroid therapy of chalazia. Amj Ophthalmol, Vol. 85, N. 6, 1978, 818-821
WATSON, P; AUSTIN J. Treatment of chalazions with injection of a steroid suspension. Brj Ophthalmol, Vol. 68, N.11, 1984, 833-835
DUA, S; NILAWAR, V. Nonsurgical therapy of chalazion. Amj Ophthalmol, Vol. 94, 1982, 424-425
rate research
Read More
The aim of this study is to compare the dissolution time of six formulations of paranteralSodium Ceftriaxonepreparation, the original product and five generic local ones. The dissolution time was measured precisely as the point at which the dried pow
der of Sodium Ceftriaxone preparation became a transparent solution on the addition of physiologicalsolution 0,9% of Sodium Chloride. The dissolution time of the six products were different. The measurement of infrared spectroscopy (FTIR) of different powder preparations was conducted, then the weight, the humidity and the morphology of different medical powders were studied to investigate the factors influencing the dissolution time. The difference in dissolution time between the six products was due to differences in powder characteristics such as water content, crystal shape and dimension. It was shown that one local generic product of Sodium Ceftriaxone islook like the original one.
Tow compounds have been synthesised: tetra butyl ammonium
alginate and dodecanoate sodium alginate ester.
The synthesis of compound (1) by transferring
sodium alginate to Alginic acid and then adjusted by tetra-butyl
ammonium hydroxide. The comp
ound (2) was synthesised from
tetra-butyl ammonium alginate according to Fisherest erification,
between tetra-butylammonium alginate and dodecanoic acid and
using (Amberlyst-15) as a hetrogeneous acid catalyst, and then the
product react with sodium carbonate.
Purpose : to determine the incidence of eyes that have an increase in the intraocular pressure( I.O.P ) after subtenon injection of triamcinolone acetonide . Methods: 40 patient 50 eyes treated with 40 mg subtenon injection of TA for different diseas
es. The incidence of an I.O.P elevation ≥ 5mmhg was determine, the peak of I.O.P, the relation between I.O.P elevation and the age, gender, the kind of disease and the number of we injections of ta Results : an elevation I.O.P≥ 5mmhg was found in 25 eyes ( 50%) . The I.O.P began to increase significantly from 1 month (20%) The peak of I.O.P after 3 months (80%) and returned to the baseline I.O.P in 10 months . the elevation I.O.P≥ 5 mmhg was significantly related with younger age (80%) between 40-50 years the elevation I.O.P is between females' more in cedence than males (59,59%) females and (42,8%) males, and is less incidence aftere single injection (42.8%) less than multi injection (60%) multiple No significant relation is round between the disease and the incidence of increased I.O.P . Conclusion : repeated injections of TA and injection of younger patients especially women increase the incidence of an I.O.P elevation .
Nisin peptide is one of the natural food preservative, is not toxic and produced by Lactococcus lactic during food fermentation. It has a high potency against gram-positive bacteria and spores, while its efficiency of Nisin against gram-negative b
acteria and fungi is low , currently Nisin is used as food preservative in many countries around the world for cheese products and others.
Large pre-trained language models such as BERT have been the driving force behind recent improvements across many NLP tasks. However, BERT is only trained to predict missing words -- either through masking or next sentence prediction -- and has no kn
owledge of lexical, syntactic or semantic information beyond what it picks up through unsupervised pre-training. We propose a novel method to explicitly inject linguistic information in the form of word embeddings into any layer of a pre-trained BERT. When injecting counter-fitted and dependency-based embeddings, the performance improvements on multiple semantic similarity datasets indicate that such information is beneficial and currently missing from the original model. Our qualitative analysis shows that counter-fitted embedding injection is particularly beneficial, with notable improvements on examples that require synonym resolution.
suggested questions
Log in to be able to interact and post comments
comments
Fetching comments
Sign in to be able to follow your search criteria
